Howard Kaufman, MD, of Rutgers Cancer Institute of New Jersey, discusses a subgroup analysis of efficacy results on avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma. (Abstract 80)
Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-c...
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherap...
Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.
Marie-Andrée Forget, PhD, of The University of Texas MD Anderson Cancer Center, discusses study findings on the impact of checkpoint blockade prior to adoptive cell therapy using tumo...
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their a...
